Ruimin Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruimin Guo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Yanni Sun
Department of Emergency, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publications Juan Song
Emergency Medicine, Putuo Hospital Affiliated to Shanghai Traditional Chinese Medicine University, Shanghai 200333, P.R. China
1 shared publicationJun Liu
Emergency Medicine, Putuo Hospital Affiliated to Shanghai Traditional Chinese Medicine University, Shanghai 200333, P.R. China
1 shared publication- Jun Liu
Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
1 shared publication - Jun Liu
Department of Emergency, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication Min Han
Emergency Medicine, Putuo Hospital Affiliated to Shanghai Traditional Chinese Medicine University, Shanghai 200333, P.R. China
1 shared publication
Latest Publications
- 27 July 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 122, 110700
Corrigendum to “Emodin attenuates acute lung injury in cecal-ligation and puncture rats” [Int. Immunopharmacol. 85 (2020) 106626]
- 27 July 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 122, 110700
Corrigendum to “Emodin attenuates acute lung injury in cecal-ligation and puncture rats” [Int. Immunopharmacol. 85 (2020) 106626]
- 1 August 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 85, 106626
Emodin attenuates acute lung injury in Cecal-ligation and puncture rats
- 1 August 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 85, 106626
Emodin attenuates acute lung injury in Cecal-ligation and puncture rats
- Open Access
- 25 October 2017
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 17 (1) , 209-215
Adiponectin and its receptors are involved in hypertensive vascular injury
Adipocyte-derived adiponectin (APN) is involved in the protection against cardiovascular disease, but the endogenous APN and its receptor expression in the perivascular adipocytes and their role in hypertensive vascular injury remain unclear. The present study aimed to detect endogenous APN and its receptor expression and their protective effects against hypertensive vascular injury. APN was mainly expressed in the perivascular adipocytes, while its receptors AdipoR1 and AdipoR2 were ubiquitously expressed in the blood vessels. Angiotensin II (Ang II)‑induced hypertension resulted in a significant decrease of APN and AdipoR1 and AdipoR2 in the perivascular adipocytes and vascular cells. The migration assay used demonstrated that APN attenuated Ang II‑induced vascular smooth muscle cells migration and p38 phosphorylation Furthermore, the in vivo study demonstrated that APN receptor agonist AdipoRon attenuated Ang II‑induced hypertensive vascular hypertrophy and fibrosis. Taken together, the present study indicated that perivascular adipocytes‑derived APN attenuated hypertensive vascular injury possibly via its receptor‑mediated inhibition of p38 signaling pathway.
- 25 October 2017
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 17 (1) , 209-215
Open AccessAdiponectin and its receptors are involved in hypertensive vascular injury
Adipocyte-derived adiponectin (APN) is involved in the protection against cardiovascular disease, but the endogenous APN and its receptor expression in the perivascular adipocytes and their role in hypertensive vascular injury remain unclear. The present study aimed to detect endogenous APN and its receptor expression and their protective effects against hypertensive vascular injury. APN was mainly expressed in the perivascular adipocytes, while its receptors AdipoR1 and AdipoR2 were ubiquitously expressed in the blood vessels. Angiotensin II (Ang II)‑induced hypertension resulted in a significant decrease of APN and AdipoR1 and AdipoR2 in the perivascular adipocytes and vascular cells. The migration assay used demonstrated that APN attenuated Ang II‑induced vascular smooth muscle cells migration and p38 phosphorylation Furthermore, the in vivo study demonstrated that APN receptor agonist AdipoRon attenuated Ang II‑induced hypertensive vascular hypertrophy and fibrosis. Taken together, the present study indicated that perivascular adipocytes‑derived APN attenuated hypertensive vascular injury possibly via its receptor‑mediated inhibition of p38 signaling pathway.